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Abstract: Evidence and guidelines are becoming increasingly clear about imbalance between 
the risks and benefits of inhaled corticosteroids (ICSs) in patients with COPD. While selected 
patients may benefit from ICS-containing regimens, ICSs are often inappropriately prescribed 
with – according to Belgian market research data – up to 70% of patients in current practice 
receiving ICSs, usually as a fixed combination with a long-acting β
2
-adrenoreceptor agonist. 
Studies and recommendations support withdrawal of ICSs in a large group of patients with 
COPD. However, historical habits appear difficult to change even in the light of recent scientific 
evidence. We have built a collaborative educational platform with chest physicians and primary 
care physicians to increase awareness and provide guidance and support in this matter.
Keywords: COPD, exacerbation, withdrawal, inhaled steroids, systematic review, education
Introduction
Today, there is much debate on the appropriate prescription of inhaled corticosteroid 
(ICS) in patients with COPD. While there is a group of patients in whom the addition of 
ICS to a bronchodilator treatment may be beneficial, many patients are currently using it 
without a clear current indication. Our research aimed at summarizing scientific evidence 
available on the withdrawal of ICS in such patients and at discussing current gaps in the 
understanding in order to provide guidance to physicians, applicable in daily practice.
We searched the PubMed database for clinical trials, published in English language 
in the last 20 years, with the primary focus on efficacy/safety in patients with stable 
COPD, in whom ICS had been withdrawn from triple or dual bronchodilator treatment 
and who were compared to patients who continued on ICS. Information gaps were 
identified and discussed.
Scientific rationale
How did we get this far?
For many years now, the management of patients with COPD has been a matter of 
stepwise treatment escalation. ICSs and long-acting bronchodilators (long-acting 
β
2
-adrenoreceptor agonists [LABAs] and long-acting muscarinic receptor antagonists 
[LAMAs]) are the three individual classes of inhaled medications used, alone or in 
combination, along the progressive course of the disease in order to reduce the burden 
in the individual patient.
Brusselle et al1 clearly illustrated in their analysis of the prescription patterns in the 
UK that this practice has routinely drifted patients into triple therapy. Actually, this 
happened in a progressive manner in most of the cases, regardless of the underlying 
disease severity or stage.1 Starting patients on a fixed combination of ICS/LABA was 
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identified as the main driver toward triple treatment.1 In 
addition, primary care physicians often lack spirometry at 
baseline to help differentiate asthma from COPD. This might 
favor a treatment choice that covers both diagnoses.
These discrepancies between treatment recommendations 
and real-life use of ICS were found in surveys performed 
in many countries.2,3 Along the same lines, Belgian market 
research data confirm the disconnection between guidelines 
and prescription patterns with up to 70% of newly diagnosed 
patients with COPD receiving ICS-based treatment from the 
start (Cegedim database, second quarter 2015, unpublished 
data). Local reimbursement criteria (ie, LAMA and LABA/
LAMA must receive an a priori clearance from the Belgian 
health care system as opposed to LABA or LABA/ICS) have 
obviously played a part in the shaping and persistence of 
these treatment patterns.
So far, the overuse of ICS appears to be a product of 
history. In the 1990s, indeed, ICS was prescribed in patients 
with COPD by mere analogy with asthma treatment.4 The 
evidence base was brought ex post by the ISOLDE and later 
TORCH studies, which confirmed superiority of the ICS 
alone or in combination with LABA over placebo in terms of 
exacerbation prevention.5,6 UPLIFT then demonstrated that 
LAMA used on top of a LABA/ICS combination, which had 
become usual care at that time, induced an additional reduc-
tion in exacerbations.7 However, the INSPIRE study started 
to challenge the ICS supremacy as it showed no significant 
difference in exacerbation rates with salmeterol (SAL)/
fluticasone combination versus tiotropium monotherapy in 
patients with severe to very severe COPD and a history of 
exacerbations.8 The FLAME study later showed that double 
bronchodilation with LAMA/LABA was more effective in 
preventing exacerbations of COPD than the classical LABA/
ICS combination in a selected population of patients without 
an asthmatic component.9 While evidence is available that 
stepping up from ICS/LABA into triple therapy may be 
beneficial in COPD patients,10–12 it remains to be determined 
in which patients ICS may show additional benefit on top 
of a LABA/LAMA double bronchodilation. Very recently, 
the TRIBUTE study found that triple therapy with beclom-
ethasone significantly reduced the rate of moderate-to-severe 
exacerbations compared to indacaterol/glycopyrronium dual 
bronchodilation in the upper group of COPD patients with 
severe or very severe airflow limitation and at least one 
moderate-to-severe exacerbation in the previous year.13 The 
IMPACT study, which compared triple therapy with fluti-
casone furoate/umeclidinium/vilanterol with its respective 
LAMA/LABA and LABA/ICS combinations, confirmed 
the statistically significant reduction in moderate-to-severe 
exacerbations and exacerbations leading to hospitalization in 
a COPD population at high risk for events. However, it was 
also confirmed that the addition of ICS to dual bronchodila-
tion treatment increased the risk for pneumonia.14 It has to be 
further analyzed whether the inclusion of patients currently 
treated with ICS (and for some a possible history of asthma), 
associated with the abrupt withdrawal of ICS when patients 
were randomized in the LAMA/LABA group, may have 
contributed to the higher rate of exacerbations.14,15
Making a U-turn
In the meantime, the WISDOM study and previous trials 
with smaller cohorts breached the conservative step-up 
thinking with the introduction of de-escalation of ICS treat-
ment in the management of COPD.16 The WISDOM study 
showed that LAMA/LABA double bronchodilator treatment 
is non-inferior to an LAMA plus LABA/ICS triple treatment 
in reducing the risk of moderate to severe exacerbations in 
patients with severe to very severe COPD.16 Post hoc analy-
sis showed that ICS as part of a triple regimen provided an 
incremental exacerbation benefit in only a minority (7%) and 
clearly identifiable subset of the WISDOM cohort.17 These 
were patients with severe to very severe COPD, a history 
of frequent exacerbations ($2 exacerbations/year), and a 
high blood eosinophil count ($300 cells/µL). In line with 
the WISDOM study, evidence is accumulating that certain 
COPD subtypes may differ in their responses to ICS.18–23
The 2017 report of the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) has integrated above-
mentioned evidence from the FLAME and WISDOM studies 
and proposed a stepwise approach to the overuse of ICS, 
with dose escalation and/or de-escalation strategies accord-
ing to the individual patient symptoms and exacerbation risk 
(Box 1).24 There are growing concerns about the inappropriate 
prescribing and over-use of ICS and its potential negative 
health consequences.25 Indeed, there is now strong evidence 
for increased incidence of pneumonia, along with other side 
effects, such as oropharyngeal candidiasis, hoarseness, and 
skin bruising.24,26 The evidence linking ICS use to decreased 
bone density and fractures, increased risk of diabetes, cata-
racts, and mycobacterial infection (eg, tuberculosis) is less 
strong.24 Interestingly, the risk of pneumonia associated with 
ICS use appears to be dose dependent.27 The severity of COPD 
might also be correlated to the risk of pneumonia.28
Since Suissa et al29 had demonstrated in their Quebec 
cohort of .100,000 COPD patients that the elevated inci-
dence of severe pneumonia (2.8/100 patient-years) was 
reduced by 20% and 50% (in the first month and fourth 
month, respectively) after discontinuation of ICS, it is time 
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for a more targeted use of ICS therapy in patients in whom 
the benefit outweighs the risk.
Back on track
Considering the vast pool of patients with COPD, there is a 
large subset of patients with a suboptimal benefit/risk bal-
ance with regard to ICS treatment. It is therefore needed to 
identify the right candidates for ICS withdrawal, particularly 
in the group of COPD patients receiving high doses of ICS.30 
However, evidence for guidance is limited at the moment. 
Moreover, there is resistance among physicians and patients to 
modify a longstanding treatment schedule in seemingly stable 
patients. While stepping-down from ICS is accepted in asthma 
with its fluctuating symptom pattern, many barriers might 
render this treatment modulation more complex in COPD.
Five questions from daily practice
Regardless of the decision to continue or withdraw ICS, it 
is essential to stress the value of smoking cessation (level of 
evidence A), pulmonary rehabilitation (level of evidence A), 
and adequate management of potential comorbidities in the 
management of COPD.24 Obviously, vaccination against flu 
and pneumococcus is essential, particularly in symptomatic 
patients at risk for exacerbations. Inhaled therapies are only 
effective if used correctly, and the inhaler technique should 
also be optimized at all clinical encounters and particularly 
if patients are being switched from one therapy (device) to 
another.
1. which COPD patients should be 
treated with ICS?
In patients with COPD, there is definitely a minority of 
patients in whom a clear indication for ICS therapy is 
established. These are the patients with a positive benefit/
risk balance for the use of ICS. Although this group may not 
be finally defined yet, it particularly includes the following 
two categories:
Patients who suffer from COPD and asthma
The treatment regimen of patients with a history and/or 
findings suggestive of asthma–COPD overlap should always 
consist of a combination of ICS and bronchodilator(s); 
only in these patients, LABA/ICS combination treatment is 
appropriate as initial treatment. However, this applies to an 
estimated 15%–20% of the COPD patients at most and can-
not explain the current overuse of ICS in COPD patients.22,31 
Individual criteria, such as acute broncho-reversibility, are 
not sufficient to make a co-diagnosis of asthma in a COPD 
patient.32 Although not validated, most authors propose a 
combination of different clinical and test criteria to sus-
pect asthma–COPD overlap and to introduce ICS in the 
treatment.22,33,34
Frequent exacerbators despite optimal 
bronchodilation
According to the latest GOLD recommendations, frequent 
exacerbators who remain symptomatic despite optimal 
bronchodilation (group D) are candidates for ICS.24 In these 
patients, ICS can be added on top of an LAMA/LABA 
bronchodilator combination. The benefit of triple therapy 
versus double bronchodilation in this specific group is still 
a matter of debate because the relevant scientific evidence 
is not available yet.
Validated biomarkers would help us to select those 
patients who may benefit from ICS. Subanalyses of large 
randomized trials have demonstrated a positive effect of 
ICS on the exacerbation risk in patients with high blood 
eosinophil counts, with the largest responses in patients 
with the highest blood counts;35 protective effect of double 
bronchodilation was most pronounced in patients with lower 
eosinophilia.36 However, as most of the analyses were post 
hoc and the only predefined analysis of the FLAME study 
could not demonstrate any signal for eosinophil counts, the 
debate on the role of high blood eosinophil counts in COPD 
patients is still ongoing.18,20,37 Other markers are under con-
sideration as well.38
2. which COPD patients should not be 
treated with ICS?
The use of ICS is inappropriate if the risks outweigh the 
benefits. Based on current evidence, this is probably true 
for the following:
Box 1 Role of ICS in COPD – GOLD 2017 recommendations
•	 ICS monotherapy is not recommended
•	 ICS-containing regimens are not recommended as initial 
maintenance treatment for COPD patients, except in some 
patients, such as in those with a history and/or findings suggestive 
of asthma–COPD overlap where it may be a first choice
•	 LABA/ICS may be an alternative to LAMA/LABA therapy in 
frequent exacerbators with few symptoms, but it is not preferred 
due to the risk of pneumonia (Group C)
•	 Symptomatic patients with a history of frequent exacerbations 
(Group D) can be raised to an ICS-containing triple treatment 
if their symptoms persist or if they have further exacerbations 
despite optimal bronchodilation
Notes: Data from GOLD. Global Strategy for the Diagnosis, Management, and Pre-
vention of Chronic Obstructive Pulmonary Disease (2017 Report). Global Initiative 
for Chronic Obstructive Lung Disease, Inc.; 2017.24
Abbreviations: ICS, inhaled corticosteroid; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; LABA, long-acting β2-adrenoreceptor agonist; LAMA, 
long-acting muscarinic receptor antagonist.
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Patients who suffered from severe ICS-related side 
effects
COPD patients who suffered from severe side effects, such 
as pneumonia, should no longer be treated with ICS or cau-
tiously be treated with a low-dose ICS, if the indication for 
ICS treatment was justified.29 The attention of physicians 
should be raised on the possible similarity between clinical 
features of pneumonia and symptoms of COPD exacerba-
tions. To differentiate pneumonia from acute exacerbations, 
the experts consider a chest X-ray to be mandatory.
Newly diagnosed patients
Patients with a new diagnosis of COPD should not be 
started on ICS-containing therapy. The exceptions to this 
rule are patients with obvious signs of an asthma com-
ponent. However, physicians should know that there is 
only a small minority of patients with COPD and asthma 
overlap, immediately necessitating ICS treatment. As the 
diagnosis of asthma–COPD overlap often requires longitu-
dinal follow-up,22 the introduction of ICS in these COPD 
patients can be postponed to the moment that – despite 
optimized bronchodilator therapy – symptom control is 
not achieved and an underlying asthma component is still 
suspected.
Patients without an established indication for ICS 
prescription
There is consensus that ICS does not bring benefit to COPD 
patients without any history of exacerbations.24,39 Withdrawal 
of inappropriately prescribed ICS in these subjects is strongly 
indicated and should be considered, in our opinion, on a 
case-by-case basis.
3. In which patient can we probably 
consider stopping ICS?
Many patients are receiving ICS without a clear indication 
(ie, off-label and/or outside the current recommendations). 
Moreover, doctors have often no insight into the reasons why 
ICS has been introduced in the past. In these patients, with-
drawal of ICS should be considered. Usually, these patients 
were started on ICS prior to the introduction of the recent 
guidelines, irrespective of their exacerbation frequency, and 
without optimizing the concomitant bronchodilator medica-
tion. Additionally, LAMA/LABA combinations often did 
not exist at the time ICS/LABA was initiated and may prove 
equally effective in the risk reduction of exacerbations.
Today, there is consensus that, particularly in the non-
frequent exacerbators who are managed with an optimal 
bronchodilator treatment, ICS should be tapered and finally 
withdrawn without affecting the disease (Figure 1).16
4. what is the evidence that supports an 
ICS withdrawal strategy?
The current literature on ICS withdrawal is limited. Our sys-
tematic literature search retrieved eight comparative clinical 
trials that dealt with the withdrawal of ICS in patients with 
COPD16,40–46 and two meta-analyses.47,48 Table 1 shows the 
heterogeneity of these studies with regard to design (random-
ized, controlled, or observational) and provides an overview 
of the main study characteristics. Although GOLD recom-
mendations have never advocated the use of ICS in patients 
with FEV
1
 .50%, patient populations vary from mild to very 
severe COPD and include frequent and non-frequent exac-
erbators. We also found six interesting withdrawal studies 
that were excluded on closer look. These studies did not 
25% of
patients
75% of
patients
No exacerbation
in previous year
LABA/ICS+LAMA
or LABA/ICS
Stop ICS and
consider LAMA+LABA
Consider additional
treatment and
review ICS doses
Change to LAMA+
LABA or LAMA+
LABA+ICS
LABA/ICS+
LAMA
LABA/ICS
Exacerbation
in previous year
Figure 1 Algorithm for withdrawal of ICS in symptomatic patients with COPD.a
Note: aIf asthma–COPD overlap, continue ICS therapy and monitor for potential ICS-related adverse events; percentages of patients are based on the DACCORD 
population.55
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-adrenoreceptor agonists; LAMA, long-acting muscarinic receptor antagonist.
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meet our criterion of having comparative ICS-continuation 
vs ICS-discontinuation treatment arms because all patients 
previously receiving ICS were discontinued,49–51 ICS was not 
completely discontinued,52 or the bronchodilator treatment 
was withdrawn as well.53,54
Chronologically, O’Brien et al44 were the first to describe 
ICS withdrawal in a small and underpowered group of elderly 
patients with severe airway obstruction, who were on regular 
ICS without a clear indication. They found a small decline 
in FEV
1
 during the ICS-free study interval compared to the 
ICS treatment interval (−6.28% vs 5.03%; 95% CI:	−23.28 to 
0.76; not significant [NS]), and more patients experienced an 
exacerbation of COPD symptoms (3/18 vs 0/16 patients; NS). 
The authors mentioned that patients were using short-acting 
salbutamol and ipratropium at study entry, four patients 
were on theophylline, and two on home oxygen therapy. 
We assume that these treatments were continued during all 
cross-over intervals.
The COPE study had a mixed population of patients 
with moderate to very severe COPD.43 Most patients had 
been on ICS prior to study entry, and approximately half of 
patients were on concomitant LABA maintenance treatment. 
However, it was not reported if underlying LABA treatment 
was randomly distributed across treatment groups. The risk 
for a first exacerbation was significantly increased in the 
ICS-discontinuation group (hazard ratio [HR] 1.5; 95% CI 
1.1–2.1). Subgroup analysis found that this effect was pre-
dominant in the patients with low FEV
1
 (HR 2.1; 95% CI 
1.1–3.6), whereas no significant effect of ICS withdrawal 
was found in the subgroup of patients with better preserved 
($50% of predicted value) FEV
1
 (HR 1.2; 95% CI 0.8–2.0). 
Altogether, 40% of the patients did not experience any 
untoward effect from ICS withdrawal.
Wouters et al42 reported the results of the COSMIC trial 
with patients at a high risk for exacerbations. Most patients 
were taking ICS before screening, and all were continuing 
LABA treatment (SAL 50 µg bid) during the entire study 
period. No LAMA treatment was reported. One year after 
randomization, ICS withdrawal resulted in a decrease of 
FEV
1
, albeit small (50 mL; 95% CI 0.01–0.10; P=0.022). 
ICS discontinuation also resulted in an increased rate of 
mild exacerbations (mean annual incidence rate: 1.3 vs 0.6; 
P=0.020) and a trend toward more moderate to severe exac-
erbations (adjusted rate ratio: 1.2; 95% CI 0.9–1.5; NS).
Similarly, in the primary care population of the WISP 
trial,41 ICS discontinuation increased the risk for exacerbations 
(relative risk [RR]: 1.48; 95% CI 1.17–1.86). The WISP trial 
consisted of patients on long-term ICS treatment and ~30% 
of patients on concomitant LABA. The authors reported that 
these LABA users were mainly found in the more severe sub-
group (FEV
1
 # 50% or at least two courses of antibiotics/oral 
steroids in the previous year). ICS discontinuation resulted in 
a non-significant increase in the rate of exacerbations in this 
subgroup (RR 1.24; 95% CI 0.96–1.41; NS). Inversely, in the 
mild COPD group, significantly more exacerbations occurred 
upon withdrawal of ICS as compared to those in the ICS- 
continuation group (RR 1.94; 95% CI 1.20–3.14). No infor-
mation is available on the protective treatment given in the 
mild group. One may assume that after ICS withdrawal, 
these patients were maintained with short-acting rescue 
medication.
Meta-analysis of above-mentioned trials by Nadeem 
et al47 found no statistical confirmation that withdrawing ICS 
in routine practice would result in important deterioration of 
patient outcomes and attributed this mainly to the differences 
in definitions, outcomes, and management.
More recently, the INSTEAD trial demonstrated that ICS 
can be safely withdrawn from a fixed ICS/LABA combina-
tion in a population with moderate COPD (FEV
1
 50%–80% 
predicted).40 There was neither increase in exacerbation risk 
(time to first moderate or severe exacerbation: HR 0.80; 
P=0.258) nor worsening of lung function (FEV
1
 change of 
9 mL at 12 weeks; 95% CI −45 to 26; non-inferior). The 
protective effect of the LABA bronchodilator turned out to 
be sufficient in this group.
The WISDOM study then showed that ICS doses can also 
be gradually decreased and withdrawn in patients with severe 
to very severe COPD who are on triple therapy.16 There was 
neither clinically significant deterioration in patient-reported 
outcomes nor statistically significant increase in exacerbation 
rates. ICS withdrawal induced a statistically significant loss 
in trough FEV
1
 of ~40 mL that was not considered clinically 
relevant and was stable over time. As mentioned earlier, post 
hoc analysis found that long-term ICS treatment may reduce 
the rate of exacerbations in a selected subgroup of patients 
with blood eosinophil counts of .300 cells/µL.18
A very recent meta-analysis of Calzetta et al48 confirmed 
that ICS withdrawal did not significantly (P.0.05) increase 
the overall rate of COPD exacerbations; however, the 
analysis detected an increased risk of severe exacerbations 
(RR .1.2).
From our systematic review of ICS withdrawal studies, 
we conclude that optimal bronchodilator treatment is an 
essential condition for successful withdrawal of ICS treat-
ment. Unfortunately, many of the older studies did not clearly 
state which – if any – underlying maintenance treatments 
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were used. Future withdrawal studies should at least take 
these weaknesses into account. Figure 2 shows a hypotheti-
cal model of the risk associated with ICS withdrawal, as a 
direct relationship between the patient risk for exacerbation 
and the level of protective bronchodilator treatment provided. 
As in the WISDOM trial, many patients can be safely with-
drawn from ICS, even patients with severe to very severe 
COPD, if a double LAMA+LABA protection is provided. 
The INSTEAD trial illustrated in a low-risk group that even 
mono-bronchodilation may be sufficient to allow for ICS 
withdrawal, whereas the COSMIC study showed that it was 
not enough to avoid exacerbations when withdrawing ICS 
in a patient group at high risk for exacerbations.
The two large real-life studies with randomized and 
prospective design, OPTIMO and DACCORD, confirmed 
that ICS can be withdrawn without increased risk of exac-
erbations, provided appropriate bronchodilator treatment is 
initiated.45,46 In these studies, the decision to withdraw the 
ICS was left at the investigators’ discretion. Therefore, these 
studies demonstrate that treating physicians have the required 
skills to select the right patients for ICS withdrawal. LABA/
LAMA combinations are used to optimize bronchodilation 
and allow for more convenient ICS withdrawal.
5. How should we withdraw patients 
from ICS?
Currently, there is no best practice guidance available for ICS 
withdrawal. The withdrawal studies do not provide further 
information, as – except in the WISDOM trial – ICS has 
been stopped abruptly.
In medical practice, data are lacking to help decide 
whether stopping long-term corticosteroid treatment abruptly 
is recommended. There are scarce indications that patients 
might be put at risk for systemic rebound effects as shown 
when patients were weaned from steroids in the run-in 
period of the ISOLDE study.49 On the other hand, outside the 
controlled-trial setting, nonadherence to treatment is common 
and many patients are not taking ICS as prescribed.52
The WISDOM study provides a clear de-escalation 
schedule that isolates the ICS component from the triple 
treatment and then gradually reduces the ICS dose (Figure 3). 
Since there is no established guidance on the withdrawal 
method to be used, we suggest tapering the dose in case 
of any doubt. Optimizing bronchodilation should prob-
ably be considered when withdrawing the ICS component 
(Figure 3).
6. How can we potentially overcome 
barriers to step down from ICS?
Since there is no established guidance on the withdrawal 
method to be used, we suggest tapering the dose in case of 
any doubt. The ICS component is uncoupled from the triple 
treatment in order to reduce the dose gradually, ie, reduce 
the ICS strength and/or the number of inhalations per day. 
The risk that unlicensed single ICS formulations are used to 
achieve this dose tapering should be considered. To avoid 
Exacerbation risk
High
Low
None LABA
COPE
WISP
LAMA+LABA
Bronchodilator protection
COSMIC WISDOMa
DACCORD
OPTIMOINSTEAD
Figure 2 Simplified model for bronchodilator protection, based on ICS withdrawal studies (Table 1).
Notes: The relative size of the ellipses corresponds with the number of patients in each study. white ellipse indicates that the exacerbation rate is similar in ICS-discontinued 
and ICS-continued groups. Yellow ellipse indicates that the exacerbation rate is higher in the ICS-discontinued group than in the ICS-continued group. aICS may be beneficial 
in a well-defined subpopulation.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-adrenoreceptor agonists; LAMA, long-acting muscarinic receptor antagonist.
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confusing the patient, it is also advised to keep the number 
of switches between inhaler types as low as possible.
Importantly, patients must be carefully counseled on 
the potential benefit of the intervention. Taking away part 
of a long-term treatment is known to cause a nocebo effect. 
Therefore, if possible, the number of inhalers should remain 
constant while reducing the ICS component.
There are arguments to review patients during the 
withdrawal (eg, every 3–6 months), but patients and physi-
cians must be aware that the benefits of ICS withdrawal are 
expected in the long run. Switching back should only be con-
sidered if there is an important medical need. An important 
loss of FEV
1
 measured at several follow-up visits, repeated 
exacerbations and persistent symptom increase, may be 
considered to accept ICS introduction.
Educational matters
From our personal experience, we conclude that organizing 
small focus groups with the primary care physicians of our 
own network is the best way to approach ICS-withdrawal 
issues. Very importantly, the general practitioners need to 
understand why pulmonologists have withdrawn ICS from 
their patient’s treatment scheme. In addition, they require 
sufficient insights and support to explain the treatment 
adjustment to their patients and help them adhere to the new 
treatment scheme.
Moreover, they will learn how to identify patients for 
ICS reduction or withdrawal themselves.
In our collaborative meeting concept, physicians bring 
their own anonymized patient cases for exploration. Scientific 
information, as described earlier, is delivered in a highly 
interactive manner. Post-meeting testing and follow-up are 
foreseen.
Action points for ICS withdrawal
This section provides some general recommendations from 
our panel.
Action points for treating physicians
Physicians should reconsider the usefulness of ICS use 
according to the 2017 GOLD report and in a personalized 
medicine perspective. In patients without an established indi-
cation for ICS, stepping down could be considered. Primary 
care physicians and specialists must be aligned in providing 
extensive patient education.
Action points for professional 
organizations and educators
More efforts are required to increase awareness on poten-
tial risks of ICS overprescription. Educational programs 
may help physicians to select the right candidates for ICS 
withdrawal and to combat ICS prescription driven by fear, 
habit, confusion about asthma–COPD overlap, or the lack of 
information on de-escalating ICS therapy. Patient monitoring 
after ICS withdrawal requires a well-organized collaboration 
between primary care and secondary care. Monitoring proj-
ects and patient registries and perhaps integrated care may 
help to improve outcomes. Fast dissemination of knowledge 
and practice recommendations among medical practitioners 
must be aimed for.
Action points for health authorities and 
pharmaceutical companies
Medication access and reimbursement should be aligned with 
current treatment recommendations.
Although ICS monotherapy is not indicated in COPD, 
appropriate formulations must be made available to isolate 
the ICS component from combination treatments and gradu-
ally reduce the dose. Close collaboration between second-
ary care and primary care should be promoted to facilitate 
early patient assessment and development of an individual 
treatment plan. Integrated care initiatives, such as e-health 
developed by the authorities in Belgium, may involve pri-
mary care physicians, pharmacists, and chest physicians to 
improve patient monitoring and achieve common goals.
2SWLPDOEURQFKRGLODWLRQZLWK/$0$/$%$
6WHS
6WHS
6WHS
,&6IUHH
•0RQLWRUHYHU\PRQWKV
•2QO\VWHSXS,&6JUDGXDOO\ LIH[DFHUEDWLRQVRU KRVSLWDOLVDWLRQ,&6ORZGRVH
,&6PHGLXPGRVH
±ZHHNV ±ZHHNV \HDU
,&6KLJKGRVH
Figure 3 De-escalation of ICS, according to wISDOM.56
Abbreviations: ICS, inhaled corticosteroid; LAMA, long-acting muscarinic receptor antagonist; LABA, long-acting β2-adrenoreceptor agonists.
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Conclusion
There is a large group of patients in whom ICS can be 
withdrawn without any untoward effects. The time is now 
to identify these patients and manage them appropriately. 
Changing historical prescription habits is difficult, but it may 
prove valuable in the future.
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